Breakthrough in cancer research

2012-06-03 13:29

Chicago - An experimental drug treatment may help keep a certain kind of aggressive breast cancer at bay, offering new hope for individual therapies against difficult tumours, said research released on Sunday.

The phase III trial comparing trastuzumab emtansine (T-DM1) to standard therapy for human epidermal growth factor receptor 2 (HER2 positive) breast cancer was presented at the American Society of Clinical Oncology conference in Chicago.

The international study randomised nearly 1 000 patients to receive either T-DM1 or standard therapy every three weeks. The subjects all had metastatic cancer that had spread to other parts of the body.

The trial found that progression-free survival in the T-DM1 group was 9.6 months, compared to 6.4 months in the standard therapy group, which study authors described as "clinically meaningful improvement."

"The drug worked. It was significantly better than a very effective approved therapy for HER2 overexpressing metastatic breast cancer," said lead study author Kimberly Blackwell, professor of medicine at Duke University.

"Also, as a clinician who takes care of a lot of breast cancer patients, I'm pleased that this drug has very little dose-limiting toxicity. Patients don't lose their hair from this drug.

"For patients facing metastatic breast cancer, this is a breakthrough."

The data on overall survival time showed 65% of T-DM1 patients were alive after two years, compared to 47.5% of the standard therapy patients, a threshold that fell short of the trial's predetermined limits for judging statistical significance.

More analysis of survival times is planned for later in the ongoing study.

  • Kekeletso.nax - 2012-06-03 14:58

    7yrs too late for my mommy, but I sure do hope and pray it will help others.

  • Antionette - 2012-06-04 01:07

    How can I get on this trial?

  • rodmangoode - 2012-06-04 14:17

    The news out of Chicago this weekend is encouraging for those with cancer and for those who support them.

  • pages:
  • 1